Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 1.92 -3.52% -0.07
CKPT closed down 5.24 percent on Wednesday, August 12, 2020, on 58 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical CKPT trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish -3.52%
Wide Bands Range Expansion -3.52%
Down 3 Days in a Row Weakness -3.52%
Oversold Stochastic Weakness -3.52%
Fell Below 50 DMA Bearish -8.57%
Wide Bands Range Expansion -8.57%
Oversold Stochastic Weakness -8.57%
Fell Below 20 DMA Bearish -10.70%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -10.70%
Outside Day Range Expansion -10.70%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Medicine Immunology Antibodies Immune System Chemotherapy Cancer Immunotherapy Epidermal Growth Factor Receptor Solid Tumor Cancers Checkpoint Inhibitor Immune Checkpoint

Is CKPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.34
52 Week Low 1.05
Average Volume 733,022
200-Day Moving Average 1.78
50-Day Moving Average 2.10
20-Day Moving Average 2.28
10-Day Moving Average 2.22
Average True Range 0.22
ADX 20.24
+DI 16.42
-DI 18.32
Chandelier Exit (Long, 3 ATRs ) 2.34
Chandelier Exit (Short, 3 ATRs ) 2.20
Upper Bollinger Band 2.69
Lower Bollinger Band 1.86
Percent B (%b) 0.16
BandWidth 36.62
MACD Line 0.02
MACD Signal Line 0.06
MACD Histogram -0.0408
Fundamentals Value
Market Cap 50.48 Million
Num Shares 25.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.81
Price-to-Sales 75.20
Price-to-Book 6.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.28
Resistance 3 (R3) 2.30 2.23 2.23
Resistance 2 (R2) 2.23 2.16 2.22 2.21
Resistance 1 (R1) 2.11 2.11 2.08 2.09 2.20
Pivot Point 2.04 2.04 2.02 2.03 2.04
Support 1 (S1) 1.92 1.97 1.89 1.90 1.78
Support 2 (S2) 1.85 1.92 1.84 1.77
Support 3 (S3) 1.73 1.85 1.75
Support 4 (S4) 1.71